Exosomal Cargo: Pro-angiogeneic, anti-inflammatory, and regenerative effects in ischemic and non-ischemic heart diseases – A comprehensive review - 11/11/23
Abstract |
Heart diseases are the primary cause of mortality and morbidity worldwide which inflict a heavy social and economic burden. Among heart diseases, most deaths are due to myocardial infarction (MI) or heart attack, which occurs when a decrement in blood flow to the heart causes injury to cardiac tissue. Despite several available diagnostic, therapeutic, and prognostic approaches, heart disease remains a significant concern. Exosomes are a kind of small extracellular vesicles released by different types of cells that play a part in intercellular communication by transferring bioactive molecules important in regenerative medicine. Many studies have reported the diagnostic, therapeutic, and prognostic role of exosomes in various heart diseases. Herein, we reviewed the roles of exosomes as new emerging agents in various types of heart diseases, including ischemic heart disease, cardiomyopathy, arrhythmia, and valvular disease, focusing on pathogenesis, therapeutic, diagnostic, and prognostic roles in different areas. We have also mentioned different routes of exosome delivery to target tissues, the effects of preconditioning and modification on exosome’s capability, exosome production in compliance with good manufacturing practice (GMP), and their ongoing clinical applications in various medical contexts to shed light on possible clinical translation.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Exosomes aid cardiac regeneration, beyond their intercellular communication function. |
• | Exo-mi-RNAs induce cardiac regeneration by angiogenesis, anti-inflammation, and anti-apoptosis. |
• | Exosomes can be injected intracardially, intraperitoneally, intravenously, or subcutaneously. |
• | Ongoing clinical trials on exosomes in heart disease explore their biomarker and regenerative potential.” |
Keywords : Exosome, MicroRNA, Stem Cells, Myocardial Infarction, Heart Failure, Cardiovascular Disease, Translational Medicine
Plan
Vol 168
Article 115801- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?